Usefulness of kestose for the patients with NAFLD and NASH

Usefulness of kestose for the patients with NAFLD and NASH - Treatment with kestose for NAFLD/NASH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027058

Enrollment

Registered

2017-04-27

Start date

2017-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease/Nonalcoholic steatohepatitis

Interventions

kestose placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as NAFLD/NASH

Exclusion criteria

Exclusion criteria: 1.Women with pregnancy or possible pregnancy 2.Patients with severe renal failure and heart failure 3.Patient who is considered to be inappropriate for entry into the trial by the investigator 4.Medical doctors decided the patients are inappropriate. 5.Patients with substantial alcohol consumption (20g/day for women or >30g/day for men). 6.Patients with poor glycemic control (HbA1c>9.0%) 7.Patients with other active hepatitis and hepatocellular carcinoma 8.Patients with history of gastrointestinal surgery 9.Patients who take nonabsorbable antibiotic

Design outcomes

Primary

Measure	Time frame
Improvement of liver enzyme	—

Secondary

Measure	Time frame
1.Changes of short-chain fatty acid (Butyric acid,Acetic acid,Propionic acid etc.) 2.Changes of pathologic and metabolic marker (HOMA-IR, NAFIC socre, NAFLD fibrosis sore, FIB-4 index, APRI index, T.Cho, LDL-Cho, HDL-Cho, TG, FFA, ferritin, fasting glucose,HbA1c, high sensitivity CRP etc.) 3.Changes of hepatic fibrosis markers 4.Changes of degree of fatty liver by abdominal ultrasound examination 5.Correlation of gut microbiota and therapeutic effect 6.Changes of body weight and BMI 7.Metabolome and protein analysis of metabolite in feces 8.Changes of bile acid 9.Correlation between expiratory noble gases, gut microbiota and NAFLD/NASH 10.Correlation between usefulness of kestose and disease prognosis in the patients with NAFLD/NASH	—

Measure

Time frame

1.Changes of short-chain fatty acid (Butyric acid,Acetic acid,Propionic acid etc.) 2.Changes of pathologic and metabolic marker (HOMA-IR, NAFIC socre, NAFLD fibrosis sore, FIB-4 index, APRI index, T.Cho, LDL-Cho, HDL-Cho, TG, FFA, ferritin, fasting glucose,HbA1c, high sensitivity CRP etc.) 3.Changes of hepatic fibrosis markers 4.Changes of degree of fatty liver by abdominal ultrasound examination 5.Correlation of gut microbiota and therapeutic effect 6.Changes of body weight and BMI 7.Metabolome and protein analysis of metabolite in feces 8.Changes of bile acid 9.Correlation between expiratory noble gases, gut microbiota and NAFLD/NASH 10.Correlation between usefulness of kestose and disease prognosis in the patients with NAFLD/NASH

—

Countries

Japan

Contacts

Public ContactTakashi Honda

Nagoya University Hospital Department of Gastroenterology and Hepatology

honda@med.nagoya-u.ac.jp+81-52-744-2169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026